Targeting DnaN for tuberculosis therapy using novel griselimycins

  title={Targeting DnaN for tuberculosis therapy using novel griselimycins},
  author={Angela Kling and Peer Lukat and Deepak V. Almeida and Armin Bauer and Evelyne Fontaine and Sylvie Sordello and Nestor Zaburannyi and Jennifer Herrmann and Silke C Wenzel and Claudia K{\"o}nig and Nicole C Ammerman and Mar{\'i}a Bel{\'e}n Barrio and Kai Borchers and Florence Bordon-Pallier and Mark Br{\"o}nstrup and Gilles Courtemanche and Martin Gerlitz and Michel Geslin and Peter Hammann and Dirk W. Heinz and Holger Hoffmann and Sylvie Klieber and Markus Kohlmann and Michael Kurz and Christine Lair and Hans Matter and Eric Nuermberger and Sandeep Tyagi and Laurent Fraisse and Jacques H. Grosset and Sophie Lagrange and Rolf M{\"u}ller},
The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy. Despite the subsequent development of a curative regimen for this disease, tuberculosis remains a worldwide problem, and the emergence of multidrug-resistant Mycobacterium tuberculosis has prioritized the need for new drugs. Here we show that new optimized derivatives from Streptomyces-derived griselimycin are highly active against M. tuberculosis, both in vitro and in vivo, by inhibiting the DNA… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 41 times over the past 90 days. VIEW TWEETS